RBC Capital Downgrades ADC Therapeutics to Sector Perform, Lowers Price Target to $2

Benzinga Newsdesk www.benzinga.com Negative 94.6%

Neg 94.6% Neu 0% Pos 0%

RBC Capital analyst Leonid Timashev downgrades ADC Therapeutics (NYSE:ADCT) from Outperform to Sector Perform and lowers the price target from $6 to $2.